RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange vide notes to Accounts in the Unaudited Financial Results for the quarter ended June 30, 2008 (taken on record by the Board of Directors of the Company at its meeting held on July 29 2008) that: "Pursuant to the Announcements "Accounting for Derivatives" by the Institute of Chartered Accountants of India, the Company intends to go for an early adoption of Accounting Standard 30 on Financial Instruments: Recognition and Measurement ("AS 30") Pending adoption of AS 30 (when appropriate accounting would be carried out ), it is pertinent to disclo

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 29, 2008, titled "Q2 2008 Global Sales at USD 440 Mn (Rs 18,296 Mn), + 11%; Operating Profit after Tax steady at USD 39 Mn (Rs 1,608 Mn); Company brings certainty by settling litigation with Pfizer on worlds largest selling drug Atorvastatin, with Annual Sales of USD 12.7 Bn; Landmark deal with Daiichi Sankyo to benefit Ranbaxy in charting a higher trajectory of growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and o

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the half year ended on 30-JUN-2008 as follows: Net Sales of Rs. 220420.7 lacs for half year ending on 30-JUN-2008 against Rs. 200280 lacs for the half year ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 12715 lacs for the half year ending on 30-JUN-2008 against Rs. 40643 lacs for the half year ending on 30-JUN-2007.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 121692.1 lacs for quarter ending on 30-JUN-2008 against Rs. 101463 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 2372.8 lacs for the quarter ending on 30-JUN-2008 against Rs. 29115 lacs for the quarter ending on 30-JUN-2007.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 28, 2008, titled "Ranbaxy launches Omeprazole 40 MG Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_28072008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 23, 2008, titled "Ranbaxy Launches Generic Amlodipine Tablets on Day-1 in Japan - First independently developed generic product outside of Japan to have received marketing approvals of MHLW (Japan)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_23072008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 22, 2008, titled "Ranbaxy Wins UK SFO Case". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Pr_22072008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange with reference to the news report " Star Ledger Report of July 16 on 'Congress Probe on FDA' " that: "We are not aware of any Congressional Committee inquiry and have not received any communication in this regard. Ranbaxy is a highly regarded Company that has always believed in upholding the highest standards of quality. All our plants are CGMP compliant and produce medicines that meet global norms. During the past 3 years, the FDA has gathered over 200 random samples of various products marketed by the company in the US. These products have b

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 17, 2008, titled "Daiichi Sankyo and Ranbaxy confirm Deal is Binding and Final Allay market rumour and speculation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RAN_PR_17072008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that: "The Members of the Company at the Extra-ordinary General Meeting (EGM) held today i.e. July 15, 2008, have unanimously approved all the Resolutions proposed in the Notice dated June 16, 2008; brief details of the same are given below: 1) Issue of following Securities on a preferential basis to Daiichi Sankyo Company Limited, Japan, as per details given below: a) 46,258,063 fully paid Equity Shares of Rs. 5 each at a premium of Rs. 732 per share; b) 23,834,333 Warrants - each Warrant exercisable between six months to eighteen months from

News Verification : The media had reports that the US department of justice has levelled adulteration charges against the company. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated, "We wish to inform you that, 1) The Government of the United States of America ("the Government") has filed a Motion before the US District Court in the District of Maryland (

Ranbaxy Laboratories Ltd has informed the Exchange that: "In view of media reports emanating over the weekend, Ranbaxy would like to clarify its position and put things in the correct perspective. Ranbaxy strongly denies the allegations contained in the Motion that has been filed (Not granted) by the US Department of Justice (DOJ), seeking certain documents. No legal proceedings in the sense of a prosecution have been initiated. The Company continues to cooperate with the DOJ in regards to the investigation and has agreed to produce the specific documents sought by the Motion." The further d

Ranbaxy Laboratories Ltd has informed the Exchange that "The ESOPs Allotment Committee of Directors meeting held today i.e. July 10, 2008 has allotted 8,31,918 Equity Shares on exercise of stock options under the Employees Stock Options Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 374069788 Equity Shares of Rs.5 each aggregating Rs. 1870348940".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 25, 2008, titled "Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets; "First-to-File" Status Will Provide 180-Day Marketing Exclusivity Upon Final Approval". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_25062008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of the notice of the Extraordinary General Meeting of the Company scheduled to be held on July 15, 2008. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_NOTEGM_20062008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 18, 2008, titled "Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide; Ranbaxy will Market Generic Atorvastatin in the U.S. with 180 Days Exclusivity from Nov. 30, 2011; Agreement Also Resolves Caduet, Accupril Litigation in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_18062008.zip target=NEW> For more details c

ICICI Securities Limited has informed the Exchange regarding a public announcement ("PA") being issued by them (the 'Manager to the Offer') for and on behalf of Daiichi Sankyo Company, Limited ('Daiichi Sankyo' or the 'Acquirer') pursuant to Regulation 10 and 12 of and as required under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 as amended (the 'Regulations'). The Offer: This offer (the 'Offer') is being made by the Acquirer to the equity shareholders of Ranbaxy Laboratories Limited (hereinafter referred to as 'RLL' or the 'Ta

Ranbaxy Laboratories Ltd has informed the Exchange that at the Annual General Meeting held on May 30, 2008 the shareholders passed a Special Resolution for amendments to the Employees Stock Options Schemes of the Company. In this regard Company has submitted a copy of the Special Resolution (alongwith Explanatory Statement) passed for amendment of the Employees Stock Options Schemes of the Company pursuant to the SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines 1999. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corpo

Ranbaxy Laboratories Ltd has informed the Exchange regarding Outcome of Board Meeting held on June 11, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Outcomebm_11062008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 11, 2008, titled "Ranbaxy to bring in Daiichi Sankyo Company Limited as Majority Partner Strategic Combination creates Innovator and Generic Pharma Powerhouse". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_11062008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the outcome of Annual General Meeting held on May 30, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_OutBM_30052008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 28, 2008, titled "Full Federal Court affirms the Australian Federal Court's Decision in Favor of Ranbaxy on Pfizer's Atorvastatin Patent on Appeal- Overall ruling mixed as court also upholds decision on another Pfizer patent". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_28052008.zip target=NEW> For more details click here.<

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 21, 2008, titled "Ranbaxy Strengthens Presence In Middle East Region - Launches Business Operation in Yemen". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_21052008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 12, 2008, titled "Ranbaxy & Merck Sign Anti-Infective Drug Discovery and Development Agreement". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_12052008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 25, 2008, titled "Ranbaxy Receives Final US FDA Approval To Manufacture And Market Certirizine Hydrochloride Oral Solution". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_25042008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on April 22, 2008 took note of following :- 1) Acquisition of 9,669,977 Equity Shares of Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) constituting 14.69% of the Equity Share Capital of Orchid by Solrex Pharmaceuticals Company (Solrex), a partnership firm between Solus Pharmaceuticals Ltd. and Rexcel Pharmaceuticals Ltd., wholly owned subsidiaries of the Company and 2) Disclosures made by Solrex to the Stock Exchanges and Orchid in regard to the above.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 22, 2008, titled "Q1 2008 Global Sales at USD 409 Mn (Rs 16,231 Mn), +15%; Net Profit at USD 39 Mn (Rs 1,530 Mn), +19%; Company expects significant upside from Nexium (Esomeprazole) settlement, 2nd largest selling drug in US (Sales - $5.5 Bn)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RanbaxyLTD_PR_22042008.zip target=NEW> For mo

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 98728.6 lacs for quarter ending on 31-MAR-2008 against Rs. 98817 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 10342.2 lacs for the quarter ending on 31-MAR-2008 against Rs. 11528 lacs for the quarter ending on 31-MAR-2007.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 22, 2008, titled "Ranbaxy and Orchid announces Strategic Business Alliance - To leverage respective strengths for mutually beneficial business growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_22042008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 15, 2008, titled "Ranbaxy and Astrazeneca reach Agreement in Esomeprazole Patent Litigation; Companies also sign Manufacturing and Distribution Agreements". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_15042008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that : "The ESOPs Allotment Committee of Directors meeting held today i.e. April 9, 2008 has allotted 84,211 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 373237870 Equity Shares of Rs. 5 each aggregating Rs. 1866189350."

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 09, 2008, titled "Ranbaxy and DBT Collaborate in the Area of NDDR; To Focus On Tuberculosis Disease Segment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_09042008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 08, 2008, titled "Ranbaxy becomes first foreign generic company to develop a generic product independently outside Japan and receive authorisation from MHLW - Japan; Receives first independent product authorisation for Amlodipine Tablets in Japan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_08042008.zip target=NEW> Fo

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 03, 2008, titled "Ranbaxy Launches Worlds First Bio-Generic Recombinant Injectible for the Treatment of Osteoporosis in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/RanbaxyLab_PR_03042008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that: 1) Share transfer books for the purpose of determination of entitlement of final dividend will remain closed from May 23, 2008 to May 30, 2008 (both days inclusive). 2) Annual General Meeting has been fixed May 30, 2008. Further the Company has submitted a copy of Audited Accounts for the year ended December 31, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_upd

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors of the Company at their meeting held on March 28, 2008 has recommended a final dividend of Rs.6 (Rupees Six) per share for the year ended December 31, 2007 taking the total dividend for the year to Rs. 8.50 per share of par value of Rs.5 each (2006 - total dividend Rs. 8.50 per share).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 28, 2008, titled "Ranbaxy Annual Audited Results for Year 2007; Net Profit up 67% at USD 190 Mn (Rs 7,866 MN); Global Sales record Robust Growth of 21% at USD 1619 MN (Rs 66,927 MN); Board approves Final dividend of 120% taking total dividend for 2007 to 170%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_28032008.zip targ

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 18, 2008, titled "Ranbaxy to introduce INERSAN brand in India and Nepal. Signs exclusive in-licensing agreement with CD Pharma, the Indian affiliate of US- based VSL Pharmaceuticals. First of its kind break- through drug in the Dental segment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_pr_18032008.zip target=NEW> For mo

News Verification : The media had reports that Ranbaxy Laboratories Ltd may shortly announce a bonus issue. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated, "The news item stating that the Company may shortly announce a bonus issue is speculative and incorrect."

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 19, 2008, titled "Ranbaxy Board Clears Scheme of De-merger of New Drug Discovery Research Unit; Shareholders to receive one equity share of Re.1 each in RLSRL for every four equity shares of Rs.5, held in Ranbaxy". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19022008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has acquired 758,851 shares of M/s Zenotech Laboratories Limited (Zenotech) under Open Offer made to the shareholders of Zenotech in terms of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997. Disclosure in compliance of Regulation 7(1) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997. Further the Company has informed the Exchange that 78,78,906 equity shares of Rs.10/- each of Zenotech acquired by the Company and put under the Escrow Account on November 08, 2007 pursuant to the S

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 07, 2008, titled "Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules in USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_07022008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 06, 2008, titled "Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension in USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_06022008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 21, 2008, titled "Ranbaxy Announces Settlement of Possible Imitrex(R) Litigation with Glaxosmithkline". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_21012008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the consolidated Results for the year ended on 31-DEC-2007 as follows: Net Sales of Rs. 659040 lacs for year ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 79010 lacs for the year ending on 31-DEC-2007.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the year ended on 31-DEC-2007 as follows: Net Sales of Rs. 403424 lacs for year ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 62299 lacs for the year ending on 31-DEC-2007.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 178450 lacs for quarter ending on 31-DEC-2007 against Rs. 169750 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 18780 lacs for the quarter ending on 31-DEC-2007 against Rs. 18330 lacs for the quarter ending on 31-DEC-2006.

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on January 17, 2008 inter-alia has approved the following: (1) Appointment of Dr.Brian W.Tempest as a Non-Executive Director of the Company effective January 17, 2008. Dr. Brian W. Tempest had retired from the services of the Company as Chief Mentor and Executive Vice Chairman of the Board of Directors of the Company on December 31, 2007 on completion of his term. (2) Consideration of Scheme of Arrangement for Demerger of New Drug Discovery Research Unit of the Company into a separate entity has

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 17, 2008, titled "Net Profit for the year increases 53% to Rs 7,901 MN; Global Sales at USD 1607 MN, UP 20%; Global Sales for Q4 at USD 451 MN; + 19% - Net Profit at Rs 1,878 MN". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_17012008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 99332 lacs for quarter ending on 31-DEC-2007 against Rs. 100585 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 4840 lacs for the quarter ending on 31-DEC-2007 against Rs. 13907 lacs for the quarter ending on 31-DEC-2006.